Contract drug services

Contract drug services provider WuXi Biologics announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a slowdown in biotech financing, after seeing a strong recovery in demand in the second half of last year.

FAST NEWS: WuXi Biologics boosts new projects target

The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…

January 11, 2024

2269.HK

Discover hidden China stock gems in our weekly newsletter

FAST NEWS: WuXi Biologics boosts new projects target

Recent Articles

FAST NEWS: WuXi Biologics boosts new projects target

Follow us

Subscribe to Our Free eNewsletter

Check out our content with some of our syndication partners

Categories

Newsletter

Contract drug services

FAST NEWS: WuXi Biologics boosts new projects target

Recent Articles

FAST NEWS: WuXi Biologics boosts new projects target

RELATED ARTICLES

Follow us

Subscribe to Our Free eNewsletter

Check out our content with some of our syndication partners